You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2024

Investigational Drug Information for Dipraglurant


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Dipraglurant?

Dipraglurant is an investigational drug.

There have been 5 clinical trials for Dipraglurant. The most recent clinical trial was a Phase 2 trial, which was initiated on August 6th 2021.

The most common disease conditions in clinical trials are Parkinson Disease, Dyskinesias, and Dyskinesia, Drug-Induced. The leading clinical trial sponsors are Addex Pharma S.A., Johns Hopkins University, and [disabled in preview].

There are fifteen US patents protecting this investigational drug and two hundred and sixty-one international patents.

Recent Clinical Trials for Dipraglurant
TitleSponsorPhase
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based TherapyAddex Pharma S.A.Phase 2/Phase 3
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With BlepharospasmAddex Pharma S.A.Phase 2
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based TherapyAddex Pharma S.A.Phase 2/Phase 3

See all Dipraglurant clinical trials

Clinical Trial Summary for Dipraglurant

Top disease conditions for Dipraglurant
Top clinical trial sponsors for Dipraglurant

See all Dipraglurant clinical trials

US Patents for Dipraglurant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Dipraglurant ⤷  Sign Up Glucocerebrosidase modulators and uses thereof Alectos Therapeutics Inc. (Burnaby, CA) ⤷  Sign Up
Dipraglurant ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
Dipraglurant ⤷  Sign Up Pharmaceutical formulations Auspex Pharmaceuticals, Inc. (La Jolla, CA) ⤷  Sign Up
Dipraglurant ⤷  Sign Up Composition and method for treating neurological disease Osmotica Kereskedelmi es Szolgaltato Korlatolt Feleossegu Tarsasag (Budapest, HU) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Dipraglurant

Drugname Country Document Number Estimated Expiration Related US Patent
Dipraglurant European Patent Office EP3087056 2033-12-23 ⤷  Sign Up
Dipraglurant Japan JP2017502961 2033-12-23 ⤷  Sign Up
Dipraglurant World Intellectual Property Organization (WIPO) WO2015095963 2033-12-23 ⤷  Sign Up
Dipraglurant Australia AU2017261372 2036-05-05 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.